Literature DB >> 18802711

The clinical experience of medulloblastoma treatment and the significance of time sequence for development of leptomeningeal metastasis.

Po-Chuan Hsieh1, Chieh-Tsai Wu, Kuang-Lin Lin, Tang-Her Jaing, Chen-Kan Tseng, Tai-Ngar Lui, Shih-Ming Jung.   

Abstract

OBJECTS: Among patients with medulloblastoma, an unrare aggressive central nervous system (CNS) tumor found mostly in the posterior fossa, drop metastasis from primary location to anatomically lower sites including whole spinal cord is known as a potential way for tumor to spread. There were already lots of extensive discussions regarding diagnosis and treatment for such common neurologic complication in systemic cancer; however, fewer were found about medulloblastoma. This study aimed to reexamine the possible known prognostic factors, especially drop metastasis, and defined the influence of them.
MATERIALS AND METHODS: We retrospectively review a series of 36 patients who suffered from posterior fossa medulloblastoma and found leptomeningeal metastasis in 12 of them. Incidence, diagnosis, prognostic factors, and treatments for this common complication are discussed. The magnetic resonance images (MRI) of these patients were reviewed. The time sequence between primary surgical procedure and development of MRI evidences of drop metastasis was used for subgrouping. Log-rank test was used for survival analysis.
CONCLUSIONS: By survival analysis, patients with late drop metastasis, defined as new radiologic evidence of leptomeningeal involvement after primary CNS procedures, were found to have significant survival difference to those with early metastasis defined as drop metastasis found at the time of diagnosis (log-rank test, p = 0.0047). Further stratification of patients within this group may help in evaluation of prognosis and development of different treatment strategies.

Entities:  

Mesh:

Year:  2008        PMID: 18802711     DOI: 10.1007/s00381-008-0697-2

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  25 in total

1.  The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis.

Authors:  C S Straathof; H G de Bruin; D W Dippel; C J Vecht
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

2.  Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994-2003.

Authors:  D Kombogiorgas; S Sgouros; A R Walsh; A D Hockley; M Stevens; R Grundy; A Peet; M English; D Spooner
Journal:  Childs Nerv Syst       Date:  2006-11-22       Impact factor: 1.475

3.  Leptomeningeal metastasis with urological presentation.

Authors:  J J Chua; P K Tan; W T Seow
Journal:  Singapore Med J       Date:  1997-06       Impact factor: 1.858

4.  Routine investigations of the CSF with special reference to meningeal malignancy and infectious meningitis.

Authors:  A P van Zanten; A Twijnstra; B W Ongerboer de Visser
Journal:  Acta Neurol Scand       Date:  1988-03       Impact factor: 3.209

5.  Glucosephosphate isomerase as a CSF marker for leptomeningeal metastasis.

Authors:  H B Newton; M Fleisher; M K Schwartz; M G Malkin
Journal:  Neurology       Date:  1991-03       Impact factor: 9.910

6.  Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.

Authors:  Jayne M Lamont; Charles S McManamy; Andrew D Pearson; Steven C Clifford; David W Ellison
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors.

Authors:  A Twijnstra; B W Ongerboer de Visser; A P van Zanten; A A Hart; W J Nooyen
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

Review 8.  Leptomeningeal metastases.

Authors:  Alexis Demopoulos
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 9.  Diagnosis and management of central nervous system metastases from breast cancer.

Authors:  Eric L Chang; Simon Lo
Journal:  Oncologist       Date:  2003

10.  Polyradiculopathy in leptomeningeal metastasis: the role of EMG and late response studies.

Authors:  J G Kaplan; R K Portenoy; D R Pack; T DeSouza
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

View more
  6 in total

1.  Pleiotropic role for MYCN in medulloblastoma.

Authors:  Fredrik J Swartling; Matthew R Grimmer; Christopher S Hackett; Paul A Northcott; Qi-Wen Fan; David D Goldenberg; Jasmine Lau; Selma Masic; Kim Nguyen; Slava Yakovenko; Xiao-Ning Zhe; Heather C Flynn Gilmer; Rodney Collins; Mai Nagaoka; Joanna J Phillips; Robert B Jenkins; Tarik Tihan; Scott R Vandenberg; C David James; Kohichi Tanaka; Michael D Taylor; William A Weiss; Louis Chesler
Journal:  Genes Dev       Date:  2010-05-15       Impact factor: 11.361

2.  Radiologically occult medulloblastoma with hydrocephalus: case report.

Authors:  Hirokuni Honma; Hideki Ogiwara
Journal:  Childs Nerv Syst       Date:  2017-05-29       Impact factor: 1.475

3.  Preoperative diffuse leptomeningeal spread in a medulloblastoma: Paraplegia following surgery for posterior fossa and call for newer management protocols.

Authors:  Pravin Salunke; Kirti Gupta; Priyamvadha Kovai; Sukumar Sura; Ashish Aggarwal
Journal:  J Pediatr Neurosci       Date:  2011-07

4.  Magnetic resonance imaging of pineal tumors and drop metastases: a review approach.

Authors:  Aikaterini G Solomou
Journal:  Rare Tumors       Date:  2017-10-23

5.  Pineal Gland Tumour With Drop Metastases: A Case Report.

Authors:  Shelva Meena Gurusamy; Azhany Yaakub; Wan-Hazabbah Wan Hitam; Siti Aishah Ahmad Maulana; Wan Zulkafli Wan Ibrahim
Journal:  Cureus       Date:  2022-10-03

6.  Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors.

Authors:  Michael C Burger; Pia S Zeiner; Kolja Jahnke; Marlies Wagner; Michel Mittelbronn; Joachim P Steinbach
Journal:  PLoS One       Date:  2016-06-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.